Illumina, Inc. (ILMN)

Healthcare
Diagnostics & Research
United States
Yahoo Finance  •  Trading View  •  Company site
Price
$93.00
▲ 2.00 (2.20%)
Market Cap
$14,294,099,968
Shares: 159,000,000
P/E
-17.37
P/B: 8.95
ROE
-51.54%
Current Ratio: 1.78
Fundamentals Score
28 (NEGATIVE)

Company Overview

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Headquarters: 5200 Illumina Way, San Diego, CA, 92122, United States  |  Employees: 8970  |  Website: illumina.com
Key Contacts
IR / Phone: 858 202 4500
Exchange: NMS
Industry: Diagnostics & Research
Quick Financial Snapshot
Revenue$4,372,000,000
Net Income$-1,223,000,000
Free Cash Flow$709,000,000
Book Value / Share$14.92

Balance Sheet & Liquidity

Total Liabilities$3,930,000,000
Total Equity$2,373,000,000
Debt / Equity1.10
Current Ratio1.78
Interest Coverage-8.33
Working Capital$1,199,000,000

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)-17.37
Industry P/EN/A
Forward P/E21.04
P/B8.95
Price / Sales4.86
P / FCF29.95
EV / EBITDA-31.36
Graham NumberN/A
DCF (placeholder)
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin 65.44%
Operating Margin -19.05%
Net Margin -27.97%
ROIC -15.96%
Asset Turnover 0.69

Automated Fundamental Signals (Score: 28)

Passed
  • Gross Margin 65.4%
  • P/FCF 29.95
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
Failed
  • EPS shows upward trend
  • Price CAGR -6.73%
  • ROIC -16.0%
  • P/B Ratio 8.95
  • Operating Margin -19.1%
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Overvalued)

Price Chart (Candlestick)

Technical Analysis (Score: 65)

RSI (14)43.52
SMA 5097.99
SMA 20096.72
MACD-1.26
Signal NEUTRAL
RSI 43.5, SMA trend bullish, momentum -37.6%.

Governance & Management

Governance scores: Audit: 4 | Board: 3 | Compensation: 7 | Shareholder Rights: 2
Executive Team
NameTitle
Mr. Jacob Thaysen Ph.D. CEO & Director (1975)
Mr. Ankur Dhingra CPA Chief Financial Officer (1976)
Mr. Kevin Carl Pegels Chief of Global Operations (1968)
Dr. Steven Barnard Ph.D. Chief Technology Officer (1961)
Stephanie Campos President (—)
Mr. Scott Ericksen VP & Chief Accounting Officer (1973)
Mr. Mark Field Chief Information Officer (1971)
Mr. Scott Davies Chief Legal Officer (1970)
Governance data last updated: 10/1/2025

Latest News

No news available for this company.

← Back